Acumen Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-07-06

Reporting Person: Manning Paul B (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-06	Common Stock	C	2950484	—	Acquired	3040193	Indirect
2021-07-06	Common Stock	P	312500	$16.00	Acquired	3352693	Indirect
2021-07-06	Common Stock	C	657985	—	Acquired	657985	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-06	Series A-1 Preferred Stock	$	C	1634515	Disposed		Common Stock (1634515)	Indirect
2021-07-06	Series B Preferred Stock	$	C	1315969	Disposed		Common Stock (1315969)	Indirect
2021-07-06	Series B Preferred Stock	$	C	657985	Disposed		Common Stock (657985)	Indirect

Footnotes

F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred
Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of
the Issuer's common stock. The shares had no expiration date.

F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.

F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the
manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.